The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
As of close of business last night, Avalo Therapeutics Inc’s stock clocked out at $15.05, down -2.40% from its previous closing price of $15.42. In other words, the price has decreased by -$2.40 from its previous closing price. On the day, 0.62 million shares were traded. AVTX stock price reached its highest trading level at $15.62 during the session, while it also had its lowest trading level at $14.16.
Ratios:
To gain a deeper understanding of AVTX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 14.28 and its Current Ratio is at 14.28. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on September 17, 2025, Reiterated its Buy rating but revised its target price to $25 from $15 previously.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 13 ’24 when Almenoff June Sherie bought 500 shares for $13.00 per share. The transaction valued at 6,500 led to the insider holds 1,000 shares of the business.
Almenoff June Sherie bought 500 shares of AVTX for $6,250 on Nov 12 ’24. The Director now owns 500 shares after completing the transaction at $12.50 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AVTX now has a Market Capitalization of 267890000 and an Enterprise Value of 161299216. For the stock, the TTM Price-to-Sale (P/S) ratio is 1436.42 while its Price-to-Book (P/B) ratio in mrq is 2.93. Its current Enterprise Value per Revenue stands at 840.1 whereas that against EBITDA is -2.44.
Stock Price History:
The Beta on a monthly basis for AVTX is 0.89, which has changed by 0.135849 over the last 52 weeks, in comparison to a change of 0.12121439 over the same period for the S&P500. Over the past 52 weeks, AVTX has reached a high of $19.41, while it has fallen to a 52-week low of $3.39. The 50-Day Moving Average of the stock is 10.57%, while the 200-Day Moving Average is calculated to be 84.58%.
Shares Statistics:
It appears that AVTX traded 353.65K shares on average per day over the past three months and 308600 shares per day over the past ten days. A total of 17.83M shares are outstanding, with a floating share count of 11.12M. Insiders hold about 15.48% of the company’s shares, while institutions hold 57.65% stake in the company. Shares short for AVTX as of 1760486400 were 1302301 with a Short Ratio of 3.68, compared to 1757894400 on 202456. Therefore, it implies a Short% of Shares Outstanding of 1302301 and a Short% of Float of 7.35.
Earnings Estimates
The stock of Avalo Therapeutics Inc (AVTX) is currently in the spotlight, with 3.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$1.8, with high estimates of -$1.24 and low estimates of -$2.21.
Analysts are recommending an EPS of between -$5.84 and -$7.43 for the fiscal current year, implying an average EPS of -$6.8. EPS for the following year is -$4.78, with 6.0 analysts recommending between -$1.85 and -$7.68.
